ArticleMolecular and clinical oncology2017
F18-fluorodeoxyglucose positron emission tomography/computed tomography for bone hemangiopericytoma.
Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone hemangiopericytoma (HPC) is extremely rare, and its clinical manifestations and radiographic features are nonspecific. There are few case reports about application of F18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in HPC. A total of four subjects with pathologically diagnosed bone HPC had FDG PET/CT for staging and/or restaging bone HPC. Medical records were retrospectively reviewed for radiological, pathological and follow-up information. All primary bone and metastatic lesions demonstrated high FDG avidity on PET/CT, which also revealed the adjacent soft tissue involvement and synchronous lesion. PET/CT correctly detected metastatic lesions in 1 patient. Furthermore, 3/4 patients with available laboratory data had hypocalcemia, but normal phosphorus levels when HPC existed as primary lesions or metastatic disease; however, normalization of calcium levels when they were disease-free. The results suggested that FDG PET/CT could be effectively used for staging, surveillance and detection of recurrent/metastatic disease in HPC. There may be an association between bone HPC and hypocalcemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.